COVID-19 Vaccine

GeoVax Labs Inc (NASDAQ: GOVX) announced the presentation of updates on developing its next-generation COVID-19 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 trial. The data were presented at the Vaccines Summit Boston 2023 and the Congress for the International...

An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the upcoming winter season. The shots currently used in the U.K. and U.S. target the original omicron strain, to which the XBB.1.5 or XBB.1...

The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public prosecutor opening a criminal investigation into their original agreement....

On Tuesday, the FDA amended the emergency use authorizations (EUAs) of Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE), and BioNTech SE's (NASDAQ: BNTX) COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule.  This action...

A U.S. appeals court affirmed a decision to cancel an Arbutus Biopharma Corporation (NASDAQ: ABUS) patent related to a legal fight over Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines. The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark...

The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a Biden administration official said. The investment, "Project NextGen," first announced by...

Arbutus Biopharma Corporation (NASDAQ: ABUS) and its licensee Genevant Sciences have sued Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) in the U.S. District Court for the District of New Jersey, seeking damages for infringement of five U....

YS Biopharma (NASDAQ: YS) stock is falling Monday after the company announced PIKA recombinant COVID-19 vaccine. YS Biopharma announced interim Phase 2 safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine.  The interim data were from the Phase 2 part of the...

The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk. FDA officials could decide within a few weeks and could change their mind, Wall Street Journal reported ...

President Joe Biden signed legislation requiring the Office of the Director of National Intelligence to declassify information on any possible links between a lab in China and the origins of the Covid-19 pandemic. The House and the Senate unanimously passed the legislation earlier this...

From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. "There are different customers negotiating different prices right now, which is why it's a little bit complicated,"...

The FDA has expanded the emergency use authorization (EUA) of Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) bivalent COVID-19 vaccine as a single booster dose in children under five years of age. The amended authorization is for children six months through...

Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.  Last week, while reporting Q4 earnings, Novavax raised doubts about its...

The U.S. government invested at least $31.9 billion to develop, produce, and purchase mRNA COVID-19 vaccines, including sizeable investments in the three decades before the pandemic through March 2022, according to a new BMJ study. That includes at least $337 million was invested pre-...

European Commission President Ursula von der Leyen remains silent on her dealings with Pfizer Inc (NYSE: PFE) regarding the EU's COVID-19 vaccine contract is hurting public trust. "We need to hear what went on, otherwise it's going to drag on," Reuters quoted ...